ID   MIF_HUMAN               Reviewed;         115 AA.
AC   P14174; A5Z1R8; B2R4S3; Q2V4Y5; Q6FHV0;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Macrophage migration inhibitory factor;
DE            Short=MIF;
DE            EC=5.3.2.1;
DE   AltName: Full=Glycosylation-inhibiting factor;
DE            Short=GIF;
DE   AltName: Full=L-dopachrome isomerase;
DE   AltName: Full=L-dopachrome tautomerase;
DE            EC=5.3.3.12;
DE   AltName: Full=Phenylpyruvate tautomerase;
GN   Name=MIF; Synonyms=GLIF, MMIF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=2552447; DOI=10.1073/pnas.86.19.7522;
RA   Weiser W.Y., Temple P.A., Witek-Giannotti J.S., Remold H.G.,
RA   Clark S.C., David J.R.;
RT   "Molecular cloning of a cDNA encoding a human macrophage migration
RT   inhibitory factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7522-7526(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=8234256; DOI=10.1073/pnas.90.21.10056;
RA   Mikayama T., Nakano T., Gomi H., Nakagawa Y., Liu Y.C., Iwamatsu A.,
RA   Weiser W.Y., Ishizaka K., Sato M., Ishii Y.;
RT   "Molecular cloning and functional expression of a cDNA encoding
RT   glycosylation-inhibiting factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10056-10060(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7947826; DOI=10.1021/bi00251a025;
RA   Bernhagen J., Mitchell R.A., Calandra T., Voelter W., Cerami A.,
RA   Bucala R.;
RT   "Purification, bioactivity, and secondary structure analysis of mouse
RT   and human macrophage migration inhibitory factor (MIF).";
RL   Biochemistry 33:14144-14155(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8188240; DOI=10.1006/geno.1994.1011;
RA   Paralkar V., Wistow G.J.;
RT   "Cloning the human gene for macrophage migration inhibitory factor
RT   (MIF).";
RL   Genomics 19:48-51(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Shan Z.X., Yu X.Y., Lin S.G., Lin Q.X., Fu Y.H., Tan H.H.;
RT   "The effect of macrophage migration inhibitory factor in the
RT   atherogenesis process.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Wu S.H., Xie J., Shang H.X., Li Y., Zhang Z.;
RT   "Amplification and expression of macrophage migration inhibitory
RT   factor (MIF) in tissue of squamous carcinoma of the cervix.";
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-12.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-11.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [16]
RP   PROTEIN SEQUENCE OF 3-24.
RX   PubMed=7683862; DOI=10.1006/abbi.1993.1257;
RA   Zeng F.Y., Weiser W.Y., Kratzin H., Stahl B., Karas M., Gabius H.J.;
RT   "The major binding protein of the interferon antagonist sarcolectin in
RT   human placenta is a macrophage migration inhibitory factor.";
RL   Arch. Biochem. Biophys. 303:74-80(1993).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-115.
RC   TISSUE=Lens;
RX   PubMed=7679497; DOI=10.1073/pnas.90.4.1272;
RA   Wistow G.J., Shaughnessy M., Lee D.C., Hodin J., Zelenka P.S.;
RT   "A macrophage migration inhibitory factor is expressed in the
RT   differentiating cells of the eye lens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1272-1275(1993).
RN   [18]
RP   INTERACTION WITH COPS5, AND SUBCELLULAR LOCATION.
RX   PubMed=11089976; DOI=10.1038/35041591;
RA   Kleemann R., Hausser A., Geiger G., Mischke R., Burger-Kentischer A.,
RA   Flieger O., Johannes F.-J., Roger T., Calandra T., Kapurniotu A.,
RA   Grell M., Finkelmeier D., Brunner H., Bernhagen J.;
RT   "Intracellular action of the cytokine MIF to modulate AP-1 activity
RT   and the cell cycle through Jab1.";
RL   Nature 408:211-216(2000).
RN   [19]
RP   INVOLVEMENT IN RASJ.
RX   PubMed=11508429;
RX   DOI=10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#;
RG   The British peadiatric rheumatology study group;
RA   Donn R.P., Shelley E., Ollier W.E.R., Thomson W.;
RT   "A novel 5'-flanking region polymorphism of macrophage migration
RT   inhibitory factor is associated with systemic-onset juvenile
RT   idiopathic arthritis.";
RL   Arthritis Rheum. 44:1782-1785(2001).
RN   [20]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11439086; DOI=10.1042/0264-6021:3570373;
RA   Tan T.H.P., Edgerton S.A.V., Kumari R., McAlister M.S.B., Roe S.M.,
RA   Nagl S., Pearl L.H., Selkirk M.E., Bianco A.E., Totty N.F.,
RA   Engwerda C., Gray C.A., Meyer D.J., Rowe S.M.;
RT   "Macrophage migration inhibitory factor of the parasitic nematode
RT   Trichinella spiralis.";
RL   Biochem. J. 357:373-383(2001).
RN   [21]
RP   INTERACTION WITH BNIPL.
RX   PubMed=12681488; DOI=10.1016/S0014-5793(03)00229-1;
RA   Shen L., Hu J., Lu H., Wu M., Qin W., Wan D., Li Y.-Y., Gu J.;
RT   "The apoptosis-associated protein BNIPL interacts with two cell
RT   proliferation-related proteins, MIF and GFER.";
RL   FEBS Lett. 540:86-90(2003).
RN   [22]
RP   INTERACTION WITH CD74.
RX   PubMed=12782713; DOI=10.1084/jem.20030286;
RA   Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J.,
RA   Delohery T., Chen Y., Mitchell R.A., Bucala R.;
RT   "MIF signal transduction initiated by binding to CD74.";
RL   J. Exp. Med. 197:1467-1476(2003).
RN   [23]
RP   FUNCTION, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15908412; DOI=10.1128/IAI.73.6.3783-3786.2005;
RA   Oddo M., Calandra T., Bucala R., Meylan P.R.A.;
RT   "Macrophage migration inhibitory factor reduces the growth of virulent
RT   Mycobacterium tuberculosis in human macrophages.";
RL   Infect. Immun. 73:3783-3786(2005).
RN   [24]
RP   ROLE IN SEPSIS-RELATED DEATH.
RX   PubMed=17443469; DOI=10.1086/514344;
RA   Emonts M., Sweep F.C.G.J., Grebenchtchikov N., Geurts-Moespot A.,
RA   Knaup M., Chanson A.L., Erard V., Renner P., Hermans P.W.M.,
RA   Hazelzet J.A., Calandra T.;
RT   "Association between high levels of blood macrophage migration
RT   inhibitory factor, inappropriate adrenal response, and early death in
RT   patients with severe sepsis.";
RL   Clin. Infect. Dis. 44:1321-1328(2007).
RN   [25]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH USO1.
RX   PubMed=19454686; DOI=10.4049/jimmunol.0803710;
RA   Merk M., Baugh J., Zierow S., Leng L., Pal U., Lee S.J., Ebert A.D.,
RA   Mizue Y., Trent J.O., Mitchell R., Nickel W., Kavathas P.B.,
RA   Bernhagen J., Bucala R.;
RT   "The Golgi-associated protein p115 mediates the secretion of
RT   macrophage migration inhibitory factor.";
RL   J. Immunol. 182:6896-6906(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-78, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=8766818; DOI=10.1016/0014-5793(96)00553-4;
RA   Sugimoto H., Suzuki M., Nakagawa A., Tanaka I., Nishihira J.;
RT   "Crystal structure of macrophage migration inhibitory factor from
RT   human lymphocyte at 2.1-A resolution.";
RL   FEBS Lett. 389:145-148(1996).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   PubMed=8610159; DOI=10.1073/pnas.93.7.3007;
RA   Kato Y., Muto T., Tomura T., Tsumura H., Watarai H., Mikayama T.,
RA   Ishizaka K., Kuroki R.;
RT   "The crystal structure of human glycosylation-inhibiting factor is a
RT   trimeric barrel with three 6-stranded beta-sheets.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3007-3010(1996).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=8643551; DOI=10.1073/pnas.93.11.5191;
RA   Sun H.W., Bernhagen J., Bucala R., Lolis E.;
RT   "Crystal structure at 2.6-A resolution of human macrophage migration
RT   inhibitory factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:5191-5196(1996).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=10353846; DOI=10.1021/bi990306m;
RA   Lubetsky J.B., Swope M., Dealwis C., Blake P., Lolis E.;
RT   "Pro-1 of macrophage migration inhibitory factor functions as a
RT   catalytic base in the phenylpyruvate tautomerase activity.";
RL   Biochemistry 38:7346-7354(1999).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEX WITH TAUTOMERASE
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=11170644; DOI=10.1021/jm000386o;
RA   Orita M., Yamamoto S., Katayama N., Aoki M., Takayama K., Yamagiwa Y.,
RA   Seki N., Suzuki H., Kurihara H., Sakashita H., Takeuchi M., Fujita S.,
RA   Yamada T., Tanaka A.;
RT   "Coumarin and chromen-4-one analogues as tautomerase inhibitors of
RT   macrophage migration inhibitory factor: discovery and X-ray
RT   crystallography.";
RL   J. Med. Chem. 44:540-547(2001).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH
RP   CARBONYLOXIME-BASED INHIBITORS, AND SUBUNIT.
RX   PubMed=17526494; DOI=10.1074/jbc.M701825200;
RA   Crichlow G.V., Cheng K.F., Dabideen D., Ochani M., Aljabari B.,
RA   Pavlov V.A., Miller E.J., Lolis E., Al-Abed Y.;
RT   "Alternative chemical modifications reverse the binding orientation of
RT   a pharmacophore scaffold in the active site of macrophage migration
RT   inhibitory factor.";
RL   J. Biol. Chem. 282:23089-23095(2007).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   N-ACETYL-P-BENZOQUINONE IMINE, SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=19090677; DOI=10.1021/bi8014423;
RA   Crichlow G.V., Lubetsky J.B., Leng L., Bucala R., Lolis E.J.;
RT   "Structural and kinetic analyses of macrophage migration inhibitory
RT   factor active site interactions.";
RL   Biochemistry 48:132-139(2009).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS), FUNCTION, CATALYTIC ACTIVITY,
RP   INTERACTION WITH CD74, MUTAGENESIS OF ASN-111, AND SUBUNIT.
RX   PubMed=23776208; DOI=10.1073/pnas.1221817110;
RA   Fan C., Rajasekaran D., Syed M.A., Leng L., Loria J.P., Bhandari V.,
RA   Bucala R., Lolis E.J.;
RT   "MIF intersubunit disulfide mutant antagonist supports activation of
RT   CD74 by endogenous MIF trimer at physiologic concentrations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:10994-10999(2013).
CC   -!- FUNCTION: Pro-inflammatory cytokine. Involved in the innate immune
CC       response to bacterial pathogens. The expression of MIF at sites of
CC       inflammation suggests a role as mediator in regulating the
CC       function of macrophages in host defense. Counteracts the anti-
CC       inflammatory activity of glucocorticoids. Has phenylpyruvate
CC       tautomerase and dopachrome tautomerase activity (in vitro), but
CC       the physiological substrate is not known. It is not clear whether
CC       the tautomerase activity has any physiological relevance, and
CC       whether it is important for cytokine activity.
CC       {ECO:0000269|PubMed:15908412, ECO:0000269|PubMed:17443469,
CC       ECO:0000269|PubMed:23776208}.
CC   -!- CATALYTIC ACTIVITY: Keto-phenylpyruvate = enol-phenylpyruvate.
CC   -!- CATALYTIC ACTIVITY: L-dopachrome = 5,6-dihydroxyindole-2-
CC       carboxylate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=249 uM for phenylpyruvate {ECO:0000269|PubMed:11439086};
CC         KM=168 uM for p-hydroxyphenylpyruvate
CC         {ECO:0000269|PubMed:11439086};
CC         Vmax=2113 umol/min/mg enzyme toward phenylpyruvate
CC         {ECO:0000269|PubMed:11439086};
CC         Vmax=524 umol/min/mg enzyme toward p-hydroxyphenylpyruvate
CC         {ECO:0000269|PubMed:11439086};
CC   -!- SUBUNIT: Homotrimer. Interacts with CXCR2 extracellular domain (By
CC       similarity). Interacts with the CD74 extracellular domain, COPS5
CC       and BNIPL. {ECO:0000250, ECO:0000269|PubMed:11089976,
CC       ECO:0000269|PubMed:11170644, ECO:0000269|PubMed:12681488,
CC       ECO:0000269|PubMed:12782713, ECO:0000269|PubMed:17526494,
CC       ECO:0000269|PubMed:19090677, ECO:0000269|PubMed:19454686,
CC       ECO:0000269|PubMed:23776208}.
CC   -!- INTERACTION:
CC       O43521-2:BCL2L11; NbExp=5; IntAct=EBI-372712, EBI-526420;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:15908412,
CC       ECO:0000269|PubMed:19454686, ECO:0000269|PubMed:2552447,
CC       ECO:0000269|PubMed:8234256}. Cytoplasm
CC       {ECO:0000269|PubMed:11089976, ECO:0000269|PubMed:19454686}.
CC       Note=Does not have a cleavable signal sequence and is secreted via
CC       a specialized, non-classical pathway. Secreted by macrophages upon
CC       stimulation by bacterial lipopolysaccharide (LPS), or by
CC       M.tuberculosis antigens. {ECO:0000269|PubMed:15908412}.
CC   -!- INDUCTION: Up-regulated in concanavalin-A-treated lymphocytes. Up-
CC       regulated in macrophages upon exposure to M.tuberculosis antigens.
CC       {ECO:0000269|PubMed:15908412, ECO:0000269|PubMed:2552447}.
CC   -!- DISEASE: Rheumatoid arthritis systemic juvenile (RASJ)
CC       [MIM:604302]: An inflammatory articular disorder with systemic-
CC       onset beginning before the age of 16. It represents a subgroup of
CC       juvenile arthritis associated with severe extraarticular features
CC       and occasionally fatal complications. During active phases of the
CC       disorder, patients display a typical daily spiking fever, an
CC       evanescent macular rash, lymphadenopathy, hepatosplenomegaly,
CC       serositis, myalgia and arthritis. {ECO:0000269|PubMed:11508429}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Serum levels of MIF are elevated in patients with
CC       severe sepsis or septic shock. High levels of MIF are correlated
CC       with low survival. Drugs that inhibit tautomerase activity protect
CC       against death due to sepsis.
CC   -!- SIMILARITY: Belongs to the MIF family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mif/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MIFID41365ch22q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M25639; AAA36315.1; -; mRNA.
DR   EMBL; L10612; AAA35892.1; -; mRNA.
DR   EMBL; Z23063; CAA80598.1; -; mRNA.
DR   EMBL; L19686; AAA21814.1; -; Genomic_DNA.
DR   EMBL; AF469046; AAL78635.1; -; mRNA.
DR   EMBL; EF611126; ABQ95571.1; -; mRNA.
DR   EMBL; CR456520; CAG30406.1; -; mRNA.
DR   EMBL; AK311929; BAG34870.1; -; mRNA.
DR   EMBL; CR407644; CAG28572.1; -; mRNA.
DR   EMBL; CR541651; CAG46452.1; -; mRNA.
DR   EMBL; BT007148; AAP35812.1; -; mRNA.
DR   EMBL; DQ307455; ABB96245.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW59620.1; -; Genomic_DNA.
DR   EMBL; BC000447; AAH00447.1; -; mRNA.
DR   EMBL; BC007676; AAH07676.1; -; mRNA.
DR   EMBL; BC008914; AAH08914.1; -; mRNA.
DR   EMBL; BC013976; AAH13976.1; -; mRNA.
DR   EMBL; BC022414; AAH22414.1; -; mRNA.
DR   EMBL; BC053376; AAH53376.1; -; mRNA.
DR   EMBL; M95775; AAA36179.1; -; mRNA.
DR   CCDS; CCDS13819.1; -.
DR   PIR; A48793; A48793.
DR   RefSeq; NP_002406.1; NM_002415.1.
DR   UniGene; Hs.407995; -.
DR   PDB; 1CA7; X-ray; 2.50 A; A/B/C=2-115.
DR   PDB; 1CGQ; X-ray; 2.00 A; A/B/C=2-115.
DR   PDB; 1GCZ; X-ray; 1.90 A; A/B/C=2-115.
DR   PDB; 1GD0; X-ray; 1.50 A; A/B/C=2-115.
DR   PDB; 1GIF; X-ray; 1.90 A; A/B/C=1-115.
DR   PDB; 1LJT; X-ray; 2.00 A; A/B/C=2-115.
DR   PDB; 1MIF; X-ray; 2.60 A; A/B/C=1-115.
DR   PDB; 1P1G; X-ray; 2.50 A; A/B/C=2-115.
DR   PDB; 2OOH; X-ray; 1.85 A; A/B/C=2-115.
DR   PDB; 2OOW; X-ray; 1.75 A; A/B/C=2-115.
DR   PDB; 2OOZ; X-ray; 1.80 A; A/B/C=2-115.
DR   PDB; 3B9S; X-ray; 1.80 A; A/B/C=2-115.
DR   PDB; 3CE4; X-ray; 1.55 A; A/B/C=2-115.
DR   PDB; 3DJH; X-ray; 1.25 A; A/B/C=2-115.
DR   PDB; 3DJI; X-ray; 1.95 A; A/B/C/D/E/F=2-115.
DR   PDB; 3HOF; X-ray; 1.90 A; A/B/C=1-115.
DR   PDB; 3IJG; X-ray; 1.70 A; A/B/C=2-115.
DR   PDB; 3IJJ; X-ray; 1.25 A; A/B/C=2-115.
DR   PDB; 3JSF; X-ray; 1.93 A; A/B/C=2-115.
DR   PDB; 3JSG; X-ray; 1.58 A; A/B/C=2-115.
DR   PDB; 3JTU; X-ray; 1.86 A; A/B/C=2-115.
DR   PDB; 3L5P; X-ray; 1.80 A; A/B/C=2-115.
DR   PDB; 3L5R; X-ray; 1.94 A; A/B/C=2-115.
DR   PDB; 3L5S; X-ray; 1.86 A; A/B/C=2-115.
DR   PDB; 3L5T; X-ray; 1.86 A; A/B/C=2-115.
DR   PDB; 3L5U; X-ray; 1.90 A; A/B/C=2-115.
DR   PDB; 3L5V; X-ray; 1.70 A; A/B/C=2-115.
DR   PDB; 3SMB; X-ray; 1.60 A; A/B/C=2-115.
DR   PDB; 3SMC; X-ray; 1.80 A; A/B/C=2-115.
DR   PDB; 3U18; X-ray; 1.90 A; A/B/C=2-115.
DR   PDB; 3WNR; X-ray; 2.01 A; A/B/C=2-115.
DR   PDB; 3WNS; X-ray; 1.66 A; A/B/C=2-115.
DR   PDB; 3WNT; X-ray; 2.07 A; A/B/C=2-115.
DR   PDB; 4ETG; X-ray; 1.61 A; A/B/C=2-115.
DR   PDB; 4EUI; X-ray; 1.70 A; A/B/C=2-115.
DR   PDB; 4EVG; X-ray; 1.70 A; A/B/C=2-115.
DR   PDB; 4F2K; X-ray; 1.53 A; A/B/C=2-115.
DR   PDB; 4GRN; X-ray; 1.25 A; A/B/C=2-115.
DR   PDB; 4GRO; X-ray; 2.00 A; A/B/C/D/E/F/G/H=2-115.
DR   PDB; 4GRP; X-ray; 1.27 A; A/B/C=2-115.
DR   PDB; 4GRQ; X-ray; 1.65 A; A/B/C=2-115.
DR   PDB; 4GRR; X-ray; 1.47 A; A/B/C=3-115.
DR   PDB; 4GRU; X-ray; 1.92 A; A/B/C=2-115.
DR   PDB; 4GUM; X-ray; 2.33 A; A/B/C/D/E/F/G/H/I=2-115.
DR   PDB; 4K9G; X-ray; 1.55 A; A/B/C=2-115.
DR   PDB; 4OSF; X-ray; 1.62 A; A/B/C=2-115.
DR   PDB; 4OYQ; X-ray; 1.70 A; A/B/C=2-115.
DR   PDB; 4P01; X-ray; 2.07 A; A/B/C=2-115.
DR   PDB; 4P0H; X-ray; 1.93 A; A/B/C=2-115.
DR   PDB; 4PKK; X-ray; 1.78 A; A/B/C=2-115.
DR   PDB; 4PKZ; X-ray; 1.90 A; A/B/C=2-115.
DR   PDB; 4PLU; X-ray; 1.63 A; A/B/C=2-115.
DR   PDB; 4TRF; X-ray; 1.63 A; A/B/C=2-115.
DR   PDB; 4TRU; X-ray; 1.81 A; A/B/C=2-115.
DR   PDB; 4WR8; X-ray; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=2-115.
DR   PDB; 4WRB; X-ray; 1.81 A; A/B/C=2-115.
DR   PDB; 4XX7; X-ray; 1.77 A; A/B/C=2-115.
DR   PDB; 4XX8; X-ray; 1.77 A; A/B/C=3-115.
DR   PDB; 4Z15; X-ray; 1.60 A; A/B/C=3-115.
DR   PDB; 4Z1T; X-ray; 1.50 A; A/B/C=3-115.
DR   PDB; 4Z1U; X-ray; 2.05 A; A/B/C/D/E/F=3-115.
DR   PDB; 5B4O; X-ray; 1.37 A; A/B/C=2-115.
DR   PDB; 5BS9; X-ray; 1.98 A; A/B/C=2-115.
DR   PDB; 5BSC; X-ray; 1.89 A; A/B/C=2-115.
DR   PDB; 5BSI; X-ray; 2.00 A; A/B/C/D/E/F/G/J=2-115.
DR   PDB; 5BSJ; X-ray; 2.00 A; A/B/C=2-115.
DR   PDB; 5CG4; X-ray; 2.50 A; A/B/C=2-115.
DR   PDB; 5EIZ; X-ray; 1.96 A; A/B/C=2-115.
DR   PDB; 5HVS; X-ray; 1.75 A; A/B/C=2-115.
DR   PDB; 5HVT; X-ray; 1.75 A; A/B/C=2-115.
DR   PDB; 5HVV; X-ray; 1.90 A; A/B/C=3-115.
DR   PDB; 5J7P; X-ray; 1.85 A; A/B/C=2-115.
DR   PDB; 5J7Q; X-ray; 2.05 A; A/B/C=2-115.
DR   PDBsum; 1CA7; -.
DR   PDBsum; 1CGQ; -.
DR   PDBsum; 1GCZ; -.
DR   PDBsum; 1GD0; -.
DR   PDBsum; 1GIF; -.
DR   PDBsum; 1LJT; -.
DR   PDBsum; 1MIF; -.
DR   PDBsum; 1P1G; -.
DR   PDBsum; 2OOH; -.
DR   PDBsum; 2OOW; -.
DR   PDBsum; 2OOZ; -.
DR   PDBsum; 3B9S; -.
DR   PDBsum; 3CE4; -.
DR   PDBsum; 3DJH; -.
DR   PDBsum; 3DJI; -.
DR   PDBsum; 3HOF; -.
DR   PDBsum; 3IJG; -.
DR   PDBsum; 3IJJ; -.
DR   PDBsum; 3JSF; -.
DR   PDBsum; 3JSG; -.
DR   PDBsum; 3JTU; -.
DR   PDBsum; 3L5P; -.
DR   PDBsum; 3L5R; -.
DR   PDBsum; 3L5S; -.
DR   PDBsum; 3L5T; -.
DR   PDBsum; 3L5U; -.
DR   PDBsum; 3L5V; -.
DR   PDBsum; 3SMB; -.
DR   PDBsum; 3SMC; -.
DR   PDBsum; 3U18; -.
DR   PDBsum; 3WNR; -.
DR   PDBsum; 3WNS; -.
DR   PDBsum; 3WNT; -.
DR   PDBsum; 4ETG; -.
DR   PDBsum; 4EUI; -.
DR   PDBsum; 4EVG; -.
DR   PDBsum; 4F2K; -.
DR   PDBsum; 4GRN; -.
DR   PDBsum; 4GRO; -.
DR   PDBsum; 4GRP; -.
DR   PDBsum; 4GRQ; -.
DR   PDBsum; 4GRR; -.
DR   PDBsum; 4GRU; -.
DR   PDBsum; 4GUM; -.
DR   PDBsum; 4K9G; -.
DR   PDBsum; 4OSF; -.
DR   PDBsum; 4OYQ; -.
DR   PDBsum; 4P01; -.
DR   PDBsum; 4P0H; -.
DR   PDBsum; 4PKK; -.
DR   PDBsum; 4PKZ; -.
DR   PDBsum; 4PLU; -.
DR   PDBsum; 4TRF; -.
DR   PDBsum; 4TRU; -.
DR   PDBsum; 4WR8; -.
DR   PDBsum; 4WRB; -.
DR   PDBsum; 4XX7; -.
DR   PDBsum; 4XX8; -.
DR   PDBsum; 4Z15; -.
DR   PDBsum; 4Z1T; -.
DR   PDBsum; 4Z1U; -.
DR   PDBsum; 5B4O; -.
DR   PDBsum; 5BS9; -.
DR   PDBsum; 5BSC; -.
DR   PDBsum; 5BSI; -.
DR   PDBsum; 5BSJ; -.
DR   PDBsum; 5CG4; -.
DR   PDBsum; 5EIZ; -.
DR   PDBsum; 5HVS; -.
DR   PDBsum; 5HVT; -.
DR   PDBsum; 5HVV; -.
DR   PDBsum; 5J7P; -.
DR   PDBsum; 5J7Q; -.
DR   ProteinModelPortal; P14174; -.
DR   SMR; P14174; -.
DR   BioGrid; 110428; 58.
DR   DIP; DIP-31137N; -.
DR   IntAct; P14174; 20.
DR   MINT; MINT-5000040; -.
DR   STRING; 9606.ENSP00000215754; -.
DR   BindingDB; P14174; -.
DR   ChEMBL; CHEMBL2085; -.
DR   DrugBank; DB07718; 3-(4-HYDROXY-PHENYL)PYRUVIC ACID.
DR   DrugBank; DB08334; 3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME.
DR   DrugBank; DB08333; 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME.
DR   DrugBank; DB02728; 7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester.
DR   DrugBank; DB04272; Citric Acid.
DR   iPTMnet; P14174; -.
DR   PhosphoSitePlus; P14174; -.
DR   SwissPalm; P14174; -.
DR   DMDM; 1170955; -.
DR   SWISS-2DPAGE; P14174; -.
DR   EPD; P14174; -.
DR   MaxQB; P14174; -.
DR   PaxDb; P14174; -.
DR   PeptideAtlas; P14174; -.
DR   PRIDE; P14174; -.
DR   TopDownProteomics; P14174; -.
DR   DNASU; 4282; -.
DR   Ensembl; ENST00000215754; ENSP00000215754; ENSG00000240972.
DR   Ensembl; ENST00000613839; ENSP00000482779; ENSG00000276701.
DR   GeneID; 4282; -.
DR   KEGG; hsa:4282; -.
DR   UCSC; uc002zyr.2; human.
DR   CTD; 4282; -.
DR   DisGeNET; 4282; -.
DR   GeneCards; MIF; -.
DR   H-InvDB; HIX0041297; -.
DR   HGNC; HGNC:7097; MIF.
DR   HPA; CAB005284; -.
DR   HPA; HPA003868; -.
DR   MalaCards; MIF; -.
DR   MIM; 153620; gene.
DR   MIM; 604302; phenotype.
DR   neXtProt; NX_P14174; -.
DR   OpenTargets; ENSG00000240972; -.
DR   Orphanet; 85414; Systemic-onset juvenile idiopathic arthritis.
DR   PharmGKB; PA30819; -.
DR   eggNOG; KOG1759; Eukaryota.
DR   eggNOG; ENOG41122MF; LUCA.
DR   GeneTree; ENSGT00840000129866; -.
DR   HOGENOM; HOG000112325; -.
DR   HOVERGEN; HBG003240; -.
DR   InParanoid; P14174; -.
DR   KO; K07253; -.
DR   OMA; MGKPAQY; -.
DR   OrthoDB; EOG091G0ZNJ; -.
DR   PhylomeDB; P14174; -.
DR   TreeFam; TF313853; -.
DR   BRENDA; 5.3.2.1; 2681.
DR   BRENDA; 5.3.3.12; 2681.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P14174; -.
DR   EvolutionaryTrace; P14174; -.
DR   GeneWiki; Macrophage_migration_inhibitory_factor; -.
DR   GenomeRNAi; 4282; -.
DR   PRO; PR:P14174; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000240972; -.
DR   CleanEx; HS_MIF; -.
DR   ExpressionAtlas; P14174; baseline and differential.
DR   Genevisible; P14174; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-KW.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProtKB.
DR   GO; GO:0005126; F:cytokine receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004167; F:dopachrome isomerase activity; IDA:UniProtKB.
DR   GO; GO:0050178; F:phenylpyruvate tautomerase activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0019752; P:carboxylic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090344; P:negative regulation of cell aging; IDA:BHF-UCL.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; IEA:Ensembl.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0002906; P:negative regulation of mature B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0033033; P:negative regulation of myeloid cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IDA:BHF-UCL.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; IEA:Ensembl.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0061081; P:positive regulation of myeloid leukocyte cytokine production involved in immune response; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0061078; P:positive regulation of prostaglandin secretion involved in immune response; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IDA:BHF-UCL.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0070207; P:protein homotrimerization; IPI:UniProtKB.
DR   GO; GO:0043030; P:regulation of macrophage activation; NAS:UniProtKB.
DR   InterPro; IPR001398; Macrophage_inhib_fac.
DR   InterPro; IPR019829; Macrophage_inhib_fac_CS.
DR   InterPro; IPR014347; Tautomerase/MIF_sf.
DR   PANTHER; PTHR11954; PTHR11954; 1.
DR   Pfam; PF01187; MIF; 1.
DR   ProDom; PD004816; Macrophage_inhib_fac; 1.
DR   SUPFAM; SSF55331; SSF55331; 1.
DR   PROSITE; PS01158; MIF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytokine; Cytoplasm;
KW   Direct protein sequencing; Immunity; Inflammatory response;
KW   Innate immunity; Isomerase; Reference proteome; Secreted.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:1286669}.
FT   CHAIN         2    115       Macrophage migration inhibitory factor.
FT                                /FTId=PRO_0000158062.
FT   ACT_SITE      2      2       Proton acceptor; via imino nitrogen.
FT   BINDING      33     33       Substrate.
FT   BINDING      65     65       Substrate; via amide nitrogen.
FT   BINDING      98     98       Substrate.
FT   MOD_RES      78     78       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      78     78       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P34884}.
FT   MUTAGEN     111    111       N->C: Causes formation of interchain
FT                                disulfide bonds with Cys-81 from another
FT                                subunit. {ECO:0000269|PubMed:23776208}.
FT   CONFLICT     57     59       CAL -> WAF (in Ref. 6; ABQ95571).
FT                                {ECO:0000305}.
FT   CONFLICT     67     67       K -> R (in Ref. 9; CAG46452).
FT                                {ECO:0000305}.
FT   CONFLICT     79     79       L -> Q (in Ref. 9; CAG46452).
FT                                {ECO:0000305}.
FT   CONFLICT     81     81       C -> F (in Ref. 6; ABQ95571).
FT                                {ECO:0000305}.
FT   CONFLICT    106    106       N -> S (in Ref. 1; AAA36315).
FT                                {ECO:0000305}.
FT   CONFLICT    113    113       T -> P (in Ref. 6; ABQ95571).
FT                                {ECO:0000305}.
FT   STRAND        3     10       {ECO:0000244|PDB:3DJH}.
FT   HELIX        12     14       {ECO:0000244|PDB:3DJH}.
FT   HELIX        19     31       {ECO:0000244|PDB:3DJH}.
FT   HELIX        35     37       {ECO:0000244|PDB:3DJH}.
FT   STRAND       39     43       {ECO:0000244|PDB:3DJH}.
FT   STRAND       47     50       {ECO:0000244|PDB:3DJH}.
FT   STRAND       58     66       {ECO:0000244|PDB:3DJH}.
FT   HELIX        70     88       {ECO:0000244|PDB:3DJH}.
FT   HELIX        92     94       {ECO:0000244|PDB:3DJH}.
FT   STRAND       95    101       {ECO:0000244|PDB:3DJH}.
FT   HELIX       104    106       {ECO:0000244|PDB:3DJH}.
FT   STRAND      107    109       {ECO:0000244|PDB:3DJH}.
FT   STRAND      112    114       {ECO:0000244|PDB:1GD0}.
SQ   SEQUENCE   115 AA;  12476 MW;  56D51107C05286B2 CRC64;
     MPMFIVNTNV PRASVPDGFL SELTQQLAQA TGKPPQYIAV HVVPDQLMAF GGSSEPCALC
     SLHSIGKIGG AQNRSYSKLL CGLLAERLRI SPDRVYINYY DMNAANVGWN NSTFA
//
